By Owen Tucker-Smith
OS Therapies shares surged Wednesday after the biotech company reported positive data from a clinical trial for its cancer treatment OST-HER2.
Shares of the N.Y., clinical-stage biotechnology company were recently up 60% to $6.64 in premarket trading, which is above the stock's 52-week high of $6.48.
The trial tested whether OST-HER2 could successfully treat a rare form of bone cancer that spreads to the lungs. The company reported statistically significant results in the study's primary endpoint, which measured whether patients went 12 months without the recurrence of metastatic osteosarcoma.
The company also indicated promising results from patients at the 1-year and 2-year marks.
Robert Petit, the company's chief medical and scientific officer, said that the treatment would help a population for whom there are currently no approved therapies.
OS Therapies said that it plans to seek U.S. FDA accelerated approval for OST-HER2.
Write to Owen Tucker-Smith at owen.tucker-smith@wsj.com
(END) Dow Jones Newswires
January 15, 2025 09:33 ET (14:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.